Zero New Drugs This Week, But a Class I Recall Exposes a Cross-Contamination Risk
FDA cleared no new molecular entities and no new drugs at all this week — but a Class I recall (the agency’s most severe tier) hit JB Chemicals and Pharmaceuticals after cetirizine tablets were found cross-contaminated with ranitidine. Device activity stayed brisk at 75 clearances, and Asian firms logged 17 separate FDA actions.
Coverage 2026-08-06 to 2026-08-12 (FDA publication basis) · Published 2026-08-15
No new molecular entities, no new drug approvals, and no efficacy supplements were recorded this week — a genuinely quiet week for FDA drug decisions. But quality enforcement did not slow down: drug recalls reached 49, including one Class I recall (the FDA’s most severe classification) at JB Chemicals and Pharmaceuticals, where cetirizine hydrochloride tablets were found cross-contaminated with ranitidine. Medical device clearances held at 75, and Asian companies posted 17 separate FDA actions this week.
This page is a partial excerpt from the full briefing we send to paid subscribers each week. The complete recall list, full Warning Letter detail, and the FDA approval-letter collection are member-only, as shown in the “Full Issue” section below.
THIS WEEK’S SPOTLIGHT — 4 ITEMS
Antihistamine cross-contaminated with ranitidine — this week’s only Class I recall
JB Chemicals and Pharmaceuticals Ltd recalled Cetirizine Hydrochloride Tablets USP 5mg after customer complaints of discolored tablets and red dots, which were determined to be ranitidine. Class I is the FDA’s most severe classification, reserved for a reasonable probability of serious harm or death.
Nipro and Olympus lead a 17-item Asian-company week
Nipro Medical Corporation (Japan) cleared its ELISIO™-HX hemodialyzer, and Olympus Surgical Technologies America cleared its SOLTIVE™ Laser System. Samsung Medison and Shanghai United Imaging also logged 510(k) clearances for ultrasound and PET/CT systems respectively.
All 4 Warning Letters tied to CGMP or quality issues
India’s Dabur India Limited and Woodbine Products Company were cited for manufacturing-quality (CGMP) violations; Germany’s Thomas Brunner Hygiene GmbH was cited for marketing an unapproved new drug — this week’s letters were entirely quality- and compliance-driven.
Cardiac CT-analysis software cleared via the stricter De Novo pathway
Caristo Diagnostics’ CaRi-Heart was authorized through the De Novo pathway — a higher evidentiary bar than a standard 510(k) — reflecting the novelty of AI-based coronary CT analysis.
WHAT’S IN THE FULL ISSUE
510(k) / De Novo Clearances — 4 of 75 shown
| Device | Applicant | Type | Date |
|---|---|---|---|
| V8/XV8/XH8 Ultrasound System (+4 models) | Samsung Medison | 510(k) | 2026-07-28 |
| uMI Panvivo | Shanghai United Imaging | 510(k) | 2026-07-28 |
| ELISIO™-HX | Nipro Medical Corp. | 510(k) | 2026-07-28 |
| CaRi-Heart | Caristo Diagnostics | De Novo | 2026-07-28 |
- All 49 drug recalls — including full detail on the Class I recall and 48 Class II items
- Full text of all 4 Warning Letters — company, cited violation, issuing office
- FDA Official Approval Letter Collection (PDF) — original FDA source documents with strategic commentary
- Full FDA Database (Excel) — Product Code, review timelines, applicant history
ON OUR VERIFICATION PROCESS
This briefing is generated using AI, grounded strictly in FDA primary-source data (openFDA, Federal Register, and FDA.gov). To guard against the “plausible-sounding errors” generative AI can produce, we apply three layers of verification.
No claim without a source
The AI is not permitted to generate claims absent from primary-source text. Where extraction fails, the report states so explicitly rather than filling the gap.
Automated cross-check after generation
Generated text is mechanically checked against the primary source; unsupported statements are automatically flagged and removed.
Key items verified against the original letter
New drug approvals and major efficacy supplements are checked against the actual FDA approval letter before being described.